Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
Healthcare
$22.98 +0.34%
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
52W Low $2.45High $38.33
Volume 0.58M
Average 0.33M
DMRA Pre-Tax Margin
Income before tax as a percentage of revenue.
No reported Pre-Tax Margin figures are available to summarize.
Pre-Tax Margin history
Percent of revenue · from the income statement
No Pre-Tax Margin data reported for this period type.
Pre-Tax Margin vs competitors
How DMRA compares with its peers on the latest reported figures
DMRA Competitors Peer median
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 40.7% | +21.9 pp | +90.1 pp | |
| LTM Jun 2026 | 33.8% | +6.3 pp | +16.8 pp | |
| LTM Jun 2026 | 21.9% | — | -15.5 pp | |
| LTM Mar 2026 | -35.5% | +84.1 pp | +23762.2 pp | |
| LTM Mar 2026 | -272.2% | -278.9 pp | — | |
| LTM Mar 2026 | -1123.3% | -57.5 pp | -1080.6 pp | |
DMRADamora Therapeutics, Inc. | FY2025 | — | — | — |
IRONDisc Medicine, Inc. | FY2025 | — | — | — |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | — | — | — |
| Peer median (excluding DMRA) | -6.8% | +6.3 pp | +16.8 pp | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.